Labcorp Holdings (LH) Q1 2025 Earnings Call April 29, 2025 02:09 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Q1 twenty twenty five LabCorp Holdings Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your ques ...

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the effect of the holding company reorganization on the company's business generally; (ii) the failure to receive tax-free treatment with respect to the spin-off of the company's Clinical Development and Commercialization Services business, now Fortrea Holdings Inc. for U.S. federal income purposes; (iii) the impact of spin-off rela ...

or UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the transition period from ______ to ______ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission file number 1-11353 LABCORP HOLDINGS INC. Indicate by check mark whether the registrant has submitted electronically every Interactive Data F ...

For the quarter ended March 2025, Labcorp (LH) reported revenue of $3.35 billion, up 5.3% over the same period last year. EPS came in at $3.84, compared to $3.68 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.41 billion, representing a surprise of -2.04%. The company delivered an EPS surprise of +2.95%, with the consensus EPS estimate being $3.73.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compa ...

Labcorp Holdings (LH) reported adjusted earnings per share (EPS) of $3.84 in the first quarter of 2025. The figure rose 4.3% from the year-ago reported level.The adjusted figure excludes the impacts of certain amortization expenses and restructuring charges, among others. The bottom line beat the Zacks Consensus Estimate by 2.9%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)On a GAAP basis, EPS in the first quarter was $2.52 compared with $2.69 in the year-ago period.LH Q1 Revenu ...

FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin Odonnell Media@labcorp.com Investor@labcorp.com Labcorp Announces 2025 First Quarter Results Updates Full-Year Guidance BURLINGTON, N.C., April 29, 2025 – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2025 and updated full-year guidance. "Labcorp delivered solid performance in the first quarter of 2025," said Adam Schechter, chairman and CEO of L ...

Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.84 versus $3.68 Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS: Revenue guidance of 6.7% to 8.0% Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05 Free Cash Flow of $1.10 billion to $1.25 billion Providing broader access to comprehensive testing and laboratory ser ...

Labcorp Holdings Inc. (LH) , or Labcorp, is slated to report its first-quarter 2025 results on April 29, before the opening bell.The renowned laboratory service provider reported adjusted earnings of $3.45 in the last reported quarter, topping the Zacks Consensus Estimate by 1.47%. Labcorp surpassed estimates in each of the trailing four quarters, the average surprise being 3.16%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)LH’s Q1 EstimatesThe Zacks Consensus Estimate for Labco ...

Labcorp Holdings Inc. (LH) , or Labcorp’s strong focus on key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, is poised to help it grow in the upcoming quarters. The company maintains a solid pipeline of potential acquisitions that fit its financial strategy and will enhance its organic growth. The Central Laboratories business remains the key growth driver of the Biopharma Laboratory Services (“BLS”) segment. Meanwhile, the adverse impacts of macroeconomic issue ...

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's diseaseBURLINGTON, N.C., April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. The new test further expands Labcorp's leading blood-based bi ...